The Gametocytocidal Efficacy of Different Single Doses of Primaquine with Dihydroartemisinin-piperaquine in Asymptomatic Parasite Carriers in The Gambia: A Randomized Controlled Trial

EBioMedicine. 2016 Nov:13:348-355. doi: 10.1016/j.ebiom.2016.10.032. Epub 2016 Oct 23.

Abstract

Background: Asymptomatic low-density gametocyte carriers represent the majority of malaria-infected individuals. However, the impact of recommended treatment with single low dose of primaquine and an artemisinin-based combination therapy to reduce transmission in this group is unknown.

Methods: This was a four-arm, open label, randomized controlled trial comparing the effect of dihydroartemisinin-piperaquine (DHAP) alone or combined with single dose of primaquine (PQ) at 0.20mg/kg, 0.40mg/kg, or 0.75mg/kg on Plasmodium falciparum gametocytaemia, infectiousness to mosquitoes and hemoglobin change in asymptomatic, malaria-infected, glucose-6-phosphate dehydrogenase (G6PD) normal individuals. Randomization was done using a computer-generated sequence of uneven block sizes with codes concealed in sequentially numbered opaque envelopes. The primary endpoint was the prevalence of P. falciparum gametocytemia at day 7 of follow-up determined by quantitative nucleic acid sequence based assay and analysis was by intention to treat. The trial has been concluded (registration number: NCT01838902; https://clinicaltrials.gov/ct2/show/NCT01838902).

Results: A total of 694 asymptomatic, malaria-infected individuals were enrolled. Gametocyte prevalence at day 7 was 37.0% (54/146; 95% CI 29.2-45.4), 19.0% (27/142; 95% CI 12.9-26.4), 17.2% (25/145; 95% CI 11.0-23.5) and 10.6% (15/141; 95% CI 6.1-16.9) in the DHAP alone, 0.20mg/kg, 0.40mg/kg, and 0.75mg/kg PQ arms, respectively. The main adverse events reported include headache (130/471, 27.6%), cough (73/471, 15.5%), history of fever (61/471, 13.0%) and abdominal pain (57/471, 12.1%). There were five serious adverse events however, none was related to the interventions.

Interpretation: A single course of PQ significantly reduces gametocyte carriage in malaria-infected asymptomatic, G6PD-normal individuals without increasing the risk of clinical anemia. The limited number of successful mosquito infections suggests that post-treatment transmission potential in this asymptomatic population is low.

Keywords: Asymptomatic infection; Efficacy; Gametocyte carriage; Infectivity; Malaria; Plasmodium falciparum; Primaquine; Randomized trial.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Antimalarials / administration & dosage
  • Antimalarials / adverse effects
  • Antimalarials / therapeutic use*
  • Artemisinins / administration & dosage
  • Artemisinins / adverse effects
  • Artemisinins / therapeutic use*
  • Asymptomatic Diseases*
  • Carrier State*
  • Child
  • Drug Therapy, Combination
  • Female
  • Gambia
  • Humans
  • Malaria, Falciparum / diagnosis
  • Malaria, Falciparum / drug therapy*
  • Malaria, Falciparum / parasitology*
  • Male
  • Plasmodium falciparum
  • Primaquine / administration & dosage
  • Primaquine / adverse effects
  • Primaquine / therapeutic use*
  • Quinolines / administration & dosage
  • Quinolines / adverse effects
  • Quinolines / therapeutic use*
  • Treatment Outcome

Substances

  • Antimalarials
  • Artemisinins
  • Quinolines
  • artenimol
  • piperaquine
  • Primaquine

Associated data

  • ClinicalTrials.gov/NCT01838902